Evidence map›Paper›PMID 27126975›Full record

ArticleBMJ open2016

Effect of FTY720 (fingolimod) on graft survival in renal transplant recipients: a systematic review protocol.

Reza Gholamnezhadjafari, Reza Falak, Nader Tajik, Reza Aflatoonian, Abbas Ali Keshtkar, Abbas Rezaei

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Reza GholamnezhadjafariDepartment of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran.
Reza FalakImmunology Research Center, Iran University of Medical Sciences, Tehran, Iran Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Nader TajikImmunology Research Center, Iran University of Medical Sciences, Tehran, Iran Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-7242-676X
Reza AflatoonianDepartment of Endocrinology and Female Infertility, Royan institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
Abbas Ali KeshtkarDepartment of Health Sciences Education Development, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Abbas RezaeiDepartment of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran.
Iran University of Medical Sciences · IRIsfahan University of Medical Sciences · IRRoyan Institute · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStudies have shown that FTY720 has inconsistent effects in kidney transplant recipients. Several review articles on FTY720 have been published, but most have focused on the mechanism of action of FTY720. Therefore, this review aims to evaluate and determine the beneficial and harmful effects of FTY720 therapy in kidney transplant recipients. METHODS AND ANALYSIS: We electronically searched the following databases: PubMed, Scopus, the Web of Sciences, EMBASE, Cochrane databases and the Cochrane Central Registry of Controlled Trials. Any clinical, randomised controlled trials relating to FTY720 for treating kidney transplant recipients were included without publication status or language restriction. Study selection, data extraction and assessment of study quality were performed independently by two researchers. Data were synthesised by either the fixed effects or the random effects model according to a heterogeneity test. If the extracted data were suitable for meta-analysis, STATA software was used to combine the relative risks for dichotomous outcomes, and the mean differences for continuous outcomes with 95% CIs were measured. Death, loss of function and incidence of acute kidney rejection were assessed as the primary outcomes. Renal graft function, malignancy, delayed graft function and infection were evaluated as secondary outcomes. ETHICS/DISSEMINATION: This review does not require formal ethics approval because the data are not individualised. The resulting review article will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: CRD42015024648.

Indexed as

Kidney TransplantationClinical Trials as TopicFingolimod HydrochlorideGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsSystematic Reviews as TopicFingolimod HydrochlorideImmunosuppressive AgentsFingolimodFTY720Graft survivalKidney transplantation

Identifiers

PMID27126975
PMCPMC4853966
OpenAlexW2343397911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.